A Phase II Evaluation of AMG 102 (IND Pending, NSC 750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.

Trial Profile

A Phase II Evaluation of AMG 102 (IND Pending, NSC 750009) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2016

At a glance

  • Drugs Rilotumumab (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 09 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 22 Nov 2010 Actual initiation date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 22 Nov 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top